Jessica Newcomb - 22 Sep 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Principal Accounting Officer
Issuer ticker: TNGX
Reported as of: 22 Sep 2026
Net transaction value: -$198,613
SEC form: 4
Accepted by SEC: 24 Sep 2026, 19:41:58 UTC
Prior SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Julie Fogarty, as attorney-in-fact

Key filing fact

Jessica Newcomb filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 24 Sep 2026.

Key facts

This page summarizes Jessica Newcomb's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 24 Sep 2026, 19:41.

Change

Previous filing in this sequence was filed on 24 Apr 2026.
Current net transaction value: -$198,613.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002130408 Primary reporting owner

Newcomb Jessica

Relationship: Principal Accounting Officer
Address: C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Julie Fogarty, as attorney-in-fact
Signature date: 24 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Sale

Transaction value: $15,962
Shares: -700
Change %: -1%
Price: $22.80
Shares after: 66,621
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

TNGX transaction

Common Stock

Sale

Transaction value: $122,238
Shares: -5,100
Change %: -7.7%
Price: $23.97
Shares after: 61,521
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F1, F3, F4

TNGX transaction

Common Stock

Sale

Transaction value: $60,412
Shares: -2,400
Change %: -3.9%
Price: $25.17
Shares after: 59,121
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F1, F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026.

Footnote F2

Represents the weighted average sales price per share. The shares sold at prices ranging from $22.37 to $23.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F3

The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Footnote F4

Represents the weighted average sales price per share. The shares sold at prices ranging from $23.52 to $24.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F5

Represents the weighted average sales price per share. The shares sold at prices ranging from $24.59 to $25.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.